Leading laboratory receives latest genome sequencing technology
Genome7, the most advanced next-generation sequencing (NGS) Laboratory in Southern Europe, announces that it has acquired Illumina’s NovaSeq™ 6000 to provide further scalability and flexibility to the services it provides.
NGS is changing our ideas in crucial research areas and, in the short term, having a deeper impact on all life sciences research fields. Cancer genomics is one of the most promising and fastest growing application areas. In the future, Genome7 believes that NGS-based analysis will help facilitate cancer diagnosis, prognosis and treatment, including the cancer immunotherapy revolution.
Dr. Eduardo Pareja, Coordinator of Genome7 said: “Cancer genomics is a very complex area involving different sequencing methods such as gene panels, exome, whole genome, and RNA-Seq approaches such as mRNA, miRNA, lncRNA and circRNA, and different kinds of samples such as solid tumor, liquid biopsy or FFPE archives. Single cell genomics is also a new promising approach. In this complex world, Genome7 wants to be a reference providing complete solutions from samples to findings. To have the scalability and flexibility of the Illumina NovaSeq 6000 will be a key factor.”
“Illumina is delighted to have Genome7 as the first customer in Spain to adopt our NovaSeq 6000, said Paula Dowdy, Senior Vice President and General Manager, Illumina, Europe, Middle East, and Africa. This is the most advanced sequencer we have created, and we believe it will revolutionize the study of cancer genomics.”
Genome7 will use Illumina’s NovaSeq 6000 for Cancer Genomics projects and other applications, including Bacterial Genomics SNP analysis.